Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Plans’ Formulary Restrictions Will Get More Scrutiny In 2010 Bids – CMS

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency proposes that next year’s Part D bids report new drug utilization requirements in a clear and consistent way to make it easier to assess policy compliance.

You may also be interested in...

UnitedHealth Plans “Series” Of Part D Formulary Restrictions In 2009

National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs

CMS Seeks Part D Prior Authorization Criteria Transparency In 2009

CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year

340B Showdown: HHS Facing Mounting Congressional Pressure To Halt Pharma Challenges

Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts